Our proposed primary outcome is the BRAF-NRS Fatigue Effect, which was developed with patients who have RA, although it has subsequently been validated in patients with psoriatic arthritis.42 There might also be other important outcomes, such as work productivity, that we could include in a future trial. The gene discussed is BRAF; the disease is psoriatic arthritis.